Sorafenib Global Market Report 2026

Sorafenib is a drug mainly used to treat certain types of cancer. It is categorized as a targeted therapy medication and functions by blocking specific enzymes and proteins that play a role in cancer cell proliferation and the development of blood vessels that supply tumors.

The primary product types of sorafenib include patented drugs and generic drugs. Patented drugs are medicines safeguarded by intellectual property rights, usually through a patent awarded to the company or individual responsible for discovering or developing the drug. These products are distributed through multiple channels, including hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. They are used for a range of applications, such as the treatment of kidney cancer, liver cancer, and thyroid cancer.

Tariffs have increased the cost of imported active pharmaceutical ingredients used in sorafenib manufacturing and formulation processes. These impacts are most evident in Asia Pacific manufacturing hubs that rely heavily on cross border api sourcing. Rising tariff related input costs have placed pressure on production margins and generic oncology drug pricing. This has influenced procurement strategies and capacity utilization decisions among manufacturers. However, tariffs are also encouraging domestic api production, local supplier development, and stronger pharmaceutical supply chain resilience over the long term.

The sorafenib market research report is one of a series of new reports from The Business Research Company that provides sorafenib market statistics, including sorafenib industry global market size, regional shares, competitors with a sorafenib market share, detailed sorafenib market segments, market trends and opportunities, and any further data you may need to thrive in the sorafenib industry. This sorafenib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sorafenib market size has grown steadily in recent years. It will grow from $1.29 billion in 2025 to $1.34 billion in 2026 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to clinical success of targeted kinase inhibitors, rising global cancer burden, approval of sorafenib for multiple indications, strong oncology r&d pipelines, patent-driven market expansion.

The sorafenib market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to growth in generic oncology drugs, increasing cancer diagnosis rates, focus on cost-effective cancer treatments, expansion of oncology care infrastructure, combination therapy research. Major trends in the forecast period include growing use of targeted cancer therapies, expansion of generic sorafenib products, rising adoption in liver and kidney cancer treatment, combination therapy approaches in oncology, improved access to oncology drugs in emerging markets.

The rising incidence of cancer is anticipated to drive the expansion of the sorafenib market in the coming years. Cancer is a collection of diseases marked by uncontrolled cell proliferation with the potential to invade nearby tissues and spread to other parts of the body. The growing prevalence of cancer is attributed to factors such as aging populations, lifestyle-related risks, environmental influences, and advancements in diagnostic technologies that have improved detection rates. The sorafenib market contributes to cancer treatment by offering a multi-kinase inhibitor that targets pathways involved in tumor growth and angiogenesis, providing an effective therapeutic option for advanced renal cell carcinoma and hepatocellular carcinoma. For example, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based biomedical information resource, reported that approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths occurred in the United States in 2023. Consequently, the increasing burden of cancer is fueling the growth of the sorafenib market.

The increase in healthcare spending is anticipated to drive the growth of the sorafenib market in the coming years. Healthcare expenditure refers to the overall funds allocated to healthcare services, medical treatments, equipment, and public health initiatives aimed at maintaining and improving population health. The growth in healthcare spending is largely attributed to the rising prevalence of chronic diseases, which leads to greater demand for long-term therapies, frequent clinical consultations, and expensive continuous care. Higher healthcare expenditure facilitates the adoption of sorafenib by improving access to advanced cancer treatments, supporting early diagnosis and specialist services, and enhancing patient affordability for high-cost targeted therapies. For example, in May 2024, according to the Office of National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared with an increase of 0.9% in 2022. Therefore, the growth in healthcare expenditure is contributing to the expansion of the sorafenib market.

In June 2024, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company involved in the manufacturing and sale of generic drugs, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed sum. This acquisition reinforces Lotus Pharmaceuticals' standing in the global generics market by incorporating Teva's wide-ranging pharmaceutical portfolio and operational expertise. It also broadens Lotus's market presence and product portfolio by integrating Teva's extensive oncology capabilities, including the production of sorafenib tablets. Teva Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company that produces sorafenib tablets.

Major companies operating in the sorafenib market are Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Natco Pharma, Hikma Pharmaceuticals PLC, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Accord Healthcare, Sandoz, MSN Laboratories, Alvogen

North America was the largest region in the sorafenib market in 2025. The regions covered in the sorafenib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sorafenib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sorafenib market consists of sales of nexavar, and sorafenib combination tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sorafenib Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sorafenib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sorafenib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sorafenib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Patented Drugs; Generic Drugs
• 2) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• 3) By Application: Kidney Cancer; Liver Cancer; Thyroid Cancer
• Subsegments:
• 1) By Patented Drugs: Nexavar
• 2) By Generic Drugs: Generic Sorafenib Tosylate; Other Generic Variants
• Companies Mentioned: Bayer AG; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Natco Pharma; Hikma Pharmaceuticals PLC; Beacon Pharmaceuticals Ltd.; Hetero Healthcare Ltd.; Aprazer Healthcare Private Limited; Wellona Pharma; Anant Pharmaceuticals Pvt. Ltd.; Intelicure Lifescience; Zydus Lifesciences; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma; Accord Healthcare; Sandoz; MSN Laboratories; Alvogen
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.